Eupraxia Pharmaceuticals Inc.

NASDAQ: EPRX · Healthcare · Biotechnology

Canadian filerHQ Victoria, BCCIK 0001581178Reports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

42D

FH 62DQ 11GM —SS 42

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, Altman-Z · ↓ listing tenure, filing timeliness

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$38.6M

Employees

Market cap

$224.0M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02025

Net income-$38.6M-$38.6M2025

Total assets$86.2M$86.2M2025

Liabilities$5.7M$5.7M2025

Equity$82.0M$82.0M2025

Revenue trend

FY2023 – FY2025 · USD

FY23

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Eupraxia Pharmaceuticals Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Codexis, Inc.61C Medical Facilities Corporation74B Conexeu Sciences Inc.——Sanara MedTech Inc.61C

Key facts

CEOJames A. Helliwell

SectorHealthcare

IndustryBiotechnology

HeadquartersVictoria, BC

ExchangeNASDAQ: EPRX

Employees49

IPO date2024-04-05

Latest filings

6-K2026-07-07 6-K2026-06-22 6-K2026-05-29 6-K2026-05-29 6-K2026-05-28 6-K2026-05-12 6-K2026-05-06 6-K2026-05-05

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.